Our top pick for
SuRo Capital Corp is an asset management business based in the US. SuRo Capital shares (SSSS) are listed on the NASDAQ and all prices are listed in US Dollars. SuRo Capital employs 7 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$13.50|
|52-week range||$5.36 - $14.23|
|50-day moving average||$12.75|
|200-day moving average||$13.52|
|Wall St. target price||$18.13|
|Dividend yield||$3.5 (25.74%)|
|Earnings per share (TTM)||$8.61|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-19)||2.27%|
|1 month (2021-09-27)||3.69%|
|3 months (2021-07-27)||10.75%|
|6 months (2021-04-27)||-6.70%|
|1 year (2020-10-26)||65.24%|
|2 years (2019-10-25)||103.01%|
|3 years (2018-10-26)||97.66%|
|5 years (2016-10-26)||190.32%|
Valuing SuRo Capital stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of SuRo Capital's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
SuRo Capital's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 2x. In other words, SuRo Capital shares trade at around 2x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
|Revenue TTM||$1.9 million|
|Gross profit TTM||$1.8 million|
|Return on assets TTM||-1.65%|
|Return on equity TTM||69.13%|
|Market capitalisation||$385.4 million|
TTM: trailing 12 months
There are currently 920,584 SuRo Capital shares held short by investors – that's known as SuRo Capital's "short interest". This figure is 13.1% up from 814,179 last month.
There are a few different ways that this level of interest in shorting SuRo Capital shares can be evaluated.
SuRo Capital's "short interest ratio" (SIR) is the quantity of SuRo Capital shares currently shorted divided by the average quantity of SuRo Capital shares traded daily (recently around 185601.61290323). SuRo Capital's SIR currently stands at 4.96. In other words for every 100,000 SuRo Capital shares traded daily on the market, roughly 4960 shares are currently held short.
However SuRo Capital's short interest can also be evaluated against the total number of SuRo Capital shares, or, against the total number of tradable SuRo Capital shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case SuRo Capital's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 SuRo Capital shares in existence, roughly 30 shares are currently held short) or 0.0326% of the tradable shares (for every 100,000 tradable SuRo Capital shares, roughly 33 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against SuRo Capital.
Find out more about how you can short SuRo Capital stock.
Dividend payout ratio: 55.91% of net profits
Recently SuRo Capital has paid out, on average, around 55.91% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 39.21% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), SuRo Capital shareholders could enjoy a 39.21% return on their shares, in the form of dividend payments. In SuRo Capital's case, that would currently equate to about $3.5 per share.
SuRo Capital's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
SuRo Capital's most recent dividend payout was on 29 September 2021. The latest dividend was paid out to all shareholders who bought their shares by 16 August 2021 (the "ex-dividend date").
Over the last 12 months, SuRo Capital's shares have ranged in value from as little as $5.3644 up to $14.23. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while SuRo Capital's is 1.482. This would suggest that SuRo Capital's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
SuRo Capital Corp. is a business development company. The firm seeks to invest in growing, late stage, venture capital-backed private companies. SuRo Capital Corp. was founded in 2010 and is based in San Francisco, California. .
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.